Diagnostic accuracy of a novel lateral flow assay for histoplasmosis

IF 2.7 3区医学 Q3 INFECTIOUS DISEASES Medical mycology Pub Date : 2024-05-04 DOI:10.1093/mmy/myae051

Megan Burrows, Janice Miller, Rachael M Liesman, Nathan C Bahr

引用次数: 0

Abstract

Antigen testing is an important diagnostic tool for histoplasmosis but has limited availability globally. We evaluated the OIDx urine lateral flow antigen assay among 204 persons suspected to have histoplasmosis. Among patients with proven histoplasmosis, sensitivity was 33.3% (3/9, 95% CI 7.5-70.1%) and specificity 80.5% (157/195, 95% CI 74.3-85.8%). The MiraVista urine antigen test had better specificity (96.9%) and equal sensitivity. The OIDx test demonstrated 33.3% (3/9) positive agreement and 84.0% (163/194) negative agreement with the MiraVista test. These results should be considered in the context of our low HIV prevalence population with a mixture of pulmonary and disseminated disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

组织胞浆菌病新型侧流测定的诊断准确性

抗原检测是诊断组织胞浆菌病的重要工具，但在全球范围内的可用性有限。我们对 204 名疑似组织胞浆菌病患者的 OIDx 尿液侧流抗原检测进行了评估。在已证实患有组织胞浆菌病的患者中，灵敏度为 33.3%（3/9，95% CI 7.5-70.1%），特异性为 80.5%（157/195，95% CI 74.3-85.8%）。MiraVista 尿液抗原检测的特异性更好（96.9%），灵敏度相同。OIDx 检验与 MiraVista 检验的阳性一致率为 33.3%（3/9），阴性一致率为 84.0%（163/194）。这些结果应结合我们的低 HIV 感染率人群以及肺部和播散性疾病的混合情况加以考虑。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.